Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 363

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 363
---
 standards for AI in healthcare. Heritas Argentina On July 10, 2015, Heritas Argentina was incorporated in Argentina by Fabian Fay and Martin Pablo Vazquez under registration number T98 F252 N12, establishing itself in the field of personalized medicine services focused on human genomics solutions, as well as conducting clinical studies and medical and veterinary analyses. Pursuant to the shareholders’ agreement dated December 27, 2016, the initial shareholders of Heritas Argentina were Messrs. Fay and Vazquez, each holding 17% of Heritas Argentina, and CIBIC and Instituto de Agrobiotecnología Rosario SA, each holding 33% of Heritas Argentina. On March 31, 2020, Instituto de Agrobiotecnología Rosario SA transferred their shares to Bioceres S.A., marking a significant change in shareholder composition. Bioceres S.A., an affiliate of Theo, endowed Heritas Argentina with a specialized scientific team and the necessary expertise to develop its products and services in the precision medicine industry, as well as critical assistance during the early stages of our Heritas Argentina’s operations, ensuring a successful market launch, whereas CIBIC contributed with more than 30 years of experience as a laboratory focused on clinical diagnostics and biotechnology development. Heritas Argentina focused its efforts in enabling labs to provide clinical genetic services to physicians and/or healthcare industry stakeholders, looking to transform diagnostics and treatment for patients. Its tests, adapted to the specific needs of the markets in which it operates, range from oncology to prenatal care and rare diseases, and provide precise insights that allow physicians, patients, and their families to become aware of the impact that their genes have on their conditions and how these may affect them in the future. Heritas Argentina primarily derives revenue from its diagnostics division which provides clinical genetic tests relating to the fields of oncology, prenatal care, rare diseases and human microbiome, as well as other genetic sequencing services. On April 14, 2021, the shareholders of Heritas Argentina (i.e. Bioceres SA, CIBIC, Fabian Fay and Martin Vazquez) transferred their interest in Heritas Argentina to the Parent, resulting in the Parent becoming the direct and sole shareholder of Heritas Argentina. In 2022, after several years providing clinical genetic diagnostic tests in Argentina and expanding these services into Paraguay, Heritas Argentina diversified its product portfolio by launching a new business division. Rewell, initially launched as a direct -to -consumer